Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers

Hiu Tang(Nottingham University Hospitals NHS Trust), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Omar Ahmad(Nottingham University Hospitals NHS Trust), Sarah Khan(Nottingham University Hospitals NHS Trust), Karen De Souza(Nottingham University Hospitals NHS Trust), Daniel Yeo(Nottingham University Hospitals NHS Trust), Okezie Ofor(Nottingham University Hospitals NHS Trust), Anjana Anand(Nottingham University Hospitals NHS Trust), Syed S. Karim(Nottingham University Hospitals NHS Trust)
Cancers
October 26, 2023
10.3390/cancers15215164
Cited by 17

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
|The Lancet Oncology|2015|282